#China #Beijing #Jacobio Pharma #KRAS therapies #ADC programs

Jacobio Pharma's Annual Results Overview for 2025

Jacobio Pharma, listed on the Hong Kong Stock Exchange under the symbol HKEX: 1167, has recently unveiled its annual results for the fiscal year ending December 31, 2025. This past year has been transformative for the company as it navigated significant advancements in cancer therapies and clinical development programs.

In a pivotal step, Jacobio received the approval for its first commercial product, glecirasib, a KRAS G12C inhibitor targeted at specific cancer mutations. The drug was added to China's National Reimbursement Drug List, elevating its accessibility for treatment in non-small cell lung cancer patients who have undergone prior systemic therapy. The launch represented a crucial milestone for the company as it embarks on its journey toward commercialization.

Dr. Yinxiang Wang, the Chairman and Co-CEO of Jacobio, remarked on the year as a significant moment for the firm, marking its tenth anniversary. He emphasized that the milestone achievements, including the fruitful collaboration with AstraZeneca concerning the pan-KRAS inhibitor JAB-23E73, worth a staggering total of $2.015 billion, including an upfront payment of $100 million, position the company favorably for future growth.

Key Pipeline Developments

1. Gleicirasib Updates

Glecirasib's approval for KRAS G12C-mutated non-small cell lung cancer has proved to be a game-changer for Jacobio. During the second half of the 2025 fiscal year, the company reported revenue of RMB 8.55 million linked directly to this product. Furthermore, a Phase III trial evaluating glecirasib in combination with the SHP2 inhibitor sitneprotafib is currently underway, aiming to assess its efficacy for first-line treatment.

Recent studies published in prominent medical journals such as The Lancet Respiratory Medicine and Nature Medicine reinforced the drug’s potential, showcasing a promising objective response rate of 71% with a median progression-free survival of 12.2 months.

2. JAB-23E73 Clinical Progress

The second notable mention in Jacobio's pipeline is the oral small-molecule pan-KRAS inhibitor JAB-23E73. As of January 15, 2026, 42 patients had been enrolled in its Phase I clinical trial in China, reporting manageable adverse events without major Grade 4 or 5 complications. The initial results among pancreatic cancer patients were encouraging, with an objective response rate of 38.5%. A pivotal Phase I/III trial is set for this medication, exploring its use alongside nab-paclitaxel and gemcitabine for KRAS-mutant pancreatic ductal adenocarcinoma.

3. Advanced ADC Programs

Jacobio’s innovative anticancer drug programs continue to gain momentum. The company is developing xADC platforms utilizing functional payloads to create more effective treatment modalities. Two notable upcoming submissions are:

• - JAB-BX600: A novel KRAS G12D tADC designed for targeted delivery that aims to mitigate feedback resistance encountered with traditional KRAS therapy.
• - JAB-BX467: This iADC combines HER2-targeting antibodies with a STING agonist payload intended to attract immune cells to tumors, heralding a new approach to managing previously challenging cases.

Both candidates are expected to undergo IND submissions in the latter half of 2026.

Financial Highlights

Jacobio Pharma ended 2025 with approximately RMB 1.53 billion in cash and available credit facilities. The company anticipates a balance exceeding RMB 2.0 billion by the first quarter of 2026 and is optimistic about achieving profitability through its expanding product offerings and ongoing clinical trials.

Looking Ahead

Dr. Wang concludes by asserting that Jacobio will concentrate on advancing KRAS-targeted therapies and its unique ADC portfolio. The goal remains steadfast—to broaden treatment options available to patients not only in China but globally. As the company continues to solidify its position and explore strategic partnerships, Jacobio Pharma sets the stage for significant growth and impact in the oncology landscape.

For more insights about Jacobio’s innovative projects and clinical trials, visit Jacobio Pharma's official website.